Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. American heart journal Ward, R. n., Huang, Z. n., Rockhold, F. W., Baumgartner, I. n., Berger, J. S., Blomster, J. I., Fowkes, F. G., Katona, B. G., Mahaffey, K. W., Norgren, L. n., Vemulapalli, S. n., Povsic, T. J., Mehta, R. n., Hiatt, W. R., Patel, M. R., Jones, W. S. 2019; 220: 51–58


Rates and predictors of major bleeding in patients with peripheral artery disease (PAD) treated with antiplatelets have not been well studied. This post hoc analysis of EUCLID aimed to determine the incidence of major/minor bleeding, predictors of major bleeding, and risk of major adverse cardiovascular events (MACE) following major bleeding events.EUCLID, a multicenter randomized controlled trial of 13,885 patients with symptomatic PAD, compared ticagrelor with clopidogrel for the prevention of MACE. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. Baseline characteristics were used to develop a multivariable model to determine factors associated with TIMI major bleeding. The occurrence and timing of MACE relative to a first major bleeding event were determined.TIMI major bleeding occurred in 2.3% of participants overall (0.94 event/100 patient-years). There was no significant difference in major bleeding rates by treatment assignment. Factors associated with TIMI major bleeding included older age, geographic region, Rutherford class, and ß-blocker use. Patients with TIMI major bleeding postrandomization had an increased risk of MACE (hazard ratio [HR] 4.46; 95% CI 3.40-5.84; P?

View details for DOI 10.1016/j.ahj.2019.11.007

View details for PubMedID 31783279